interleukin-12
Strand Therapeutics Raises $153M Series B to Advance mRNA Tumor Drugs
Strand Therapeutics; Series B funding; mRNA cancer therapy; STX-001; IL-12; solid tumors; Big Pharma investors; clinical trial results; biotech financing
Gilead Partners with Xilio Therapeutics for Novel Tumor-Activated IL-12 Program
interleukin-12, Xilio, XTX301, development aspects